2. Autophagy Apoptosis NF-κB PI3K/Akt/mTOR MAPK/ERK Pathway Stem Cell/Wnt
  3. Autophagy Apoptosis NF-κB PI3K Akt MEK ERK PTEN
  4. Sophocarpine

Sophocarpine is a PTEN activator and an inhibitor of PI3K/Akt, MEK/ERK, and NF-κB signaling pathways. Sophocarpine upregulates PTEN expression and inhibits PI3K/Akt phosphorylation, arrests tumor cell cycle and induces apoptosis. Sophocarpine inhibits MEK/ERK phosphorylation and VEGF secretion, reducing tumor cell migration. Sophocarpine can also inhibit NF-κB activation and p38 and JNK phosphorylation, reduce the expression of inflammatory factors such as iNOS and COX-2, and activate the Nrf2/HO-1 pathway to reduce oxidative stress. Sophocarpine has anti-tumor, anti-inflammatory, antioxidant and anti-apoptotic effects, and can be used in the research of cancers such as glioblastoma and colorectal cancer, inflammation-related diseases, and Doxorubicin (HY-15142A)-induced cardiac damage.

For research use only. We do not sell to patients.

Sophocarpine Chemical Structure

Sophocarpine Chemical Structure

CAS No. : 6483-15-4

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
5 mg In-stock
10 mg In-stock
20 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 9 publication(s) in Google Scholar

Other Forms of Sophocarpine:

Sophocarpine Related Antibodies

Top Publications Citing Use of Products

    Sophocarpine purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2023 May 3;950:175745.  [Abstract]

    Sophocarpine (20 mg/kg; i.p.; daily; one week) significantly reduces the level of oxidative stress in mice.

    Sophocarpine purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2023 May 3;950:175745.  [Abstract]

    Sophocarpine (20 mg/kg; i.p.; daily; one week) and LPS together significantly increases the expression of Nrf2 and HO-1 in mice.

    Sophocarpine purchased from MedChemExpress. Usage Cited in: Molecules. 2022, 27(22), 7868

    Sophocarpine (SOP; 20, 40 mg/kg; i.p.; once per day over two weeks) significantly hinders the ISO(Isoproterenol)-induced increase in TLR-4 and phosphorylation of NF-κB in mice.

    View All NF-κB Isoform Specific Products:

    View All Isoforms
    NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

    View All PI3K Isoform Specific Products:

    View All Isoforms
    PI3Kα PI3Kβ PI3Kγ PI3Kδ PI3KC2α PI3KC2β PI3KC2γ Vps34 PI3K PI3KC3 p120γ

    View All Akt Isoform Specific Products:

    View All Isoforms
    Akt Akt1 Akt2 Akt3

    View All MEK Isoform Specific Products:

    View All Isoforms
    MEK1 MEK2 MEK5 MEK

    View All ERK Isoform Specific Products:

    View All Isoforms
    ERK ERK1 ERK2 ERK5 ERK8

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Sophocarpine is a PTEN activator and an inhibitor of PI3K/Akt, MEK/ERK, and NF-κB signaling pathways. Sophocarpine upregulates PTEN expression and inhibits PI3K/Akt phosphorylation, arrests tumor cell cycle and induces apoptosis. Sophocarpine inhibits MEK/ERK phosphorylation and VEGF secretion, reducing tumor cell migration. Sophocarpine can also inhibit NF-κB activation and p38 and JNK phosphorylation, reduce the expression of inflammatory factors such as iNOS and COX-2, and activate the Nrf2/HO-1 pathway to reduce oxidative stress. Sophocarpine has anti-tumor, anti-inflammatory, antioxidant and anti-apoptotic effects, and can be used in the research of cancers such as glioblastoma and colorectal cancer, inflammation-related diseases, and Doxorubicin (HY-15142A)-induced cardiac damage[1][2][3][4].

    IC50 & Target[1]

    PI3K

     

    Cellular Effect
    Cell Line Type Value Description References
    A549 IC50
    > 40 μM
    Compound: 6
    Antiproliferative activity against human A549 cells after 3 days by SRB assay
    Antiproliferative activity against human A549 cells after 3 days by SRB assay
    		[PMID: 26865176]
    KB IC50
    > 40 μM
    Compound: 6
    Antiproliferative activity against human KB cells after 3 days by SRB assay
    Antiproliferative activity against human KB cells after 3 days by SRB assay
    		[PMID: 26865176]
    MDA-MB-231 IC50
    > 40 μM
    Compound: 6
    Antiproliferative activity against human MDA-MB-231 cells after 3 days by SRB assay
    Antiproliferative activity against human MDA-MB-231 cells after 3 days by SRB assay
    		[PMID: 26865176]
    RAW264.7 IC50
    > 200 μM
    Compound: 2
    Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha production after 6 hrs by ELISA
    Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha production after 6 hrs by ELISA
    		[PMID: 21036613]
    In Vitro

    Sophocarpine (0.5-4 mM; 24-48 h) inhibits cell viability, proliferation and migration, induces cell cycle G0/G1 arrest and apoptosis, upregulates PTEN and downregulates PI3K/Akt signaling pathways in glioblastoma cells (U251, C6)[1].
    Sophocarpine (0.4 mM; 24-72 h) inhibits cell proliferation and migration, downregulates MEK/ERK phosphorylation and VEGF-A/C/D secretion, and reduces N-cadherin and MMP-9 expression in colorectal cancer cells (HCT116, SW620)[2].
    Sophocarpine (50-100 μg/mL; 24 h) inhibits LPS-induced NO, TNF-α, and IL-6 production in RAW 264.7 macrophages, downregulates iNOS and COX-2 protein expression, and inhibits NF-κB activation and p38 and JNK phosphorylation in RAW 264.7 macrophages[3].
    Sophocarpine (1-5 μM; 24 h pretreatment + 12 h DOX cotreatment) reduces ROS levels in H9C2 cardiomyocytes, upregulates Nrf2/HO-1 signaling, inhibits DOX (HY-15142A)-induced Bax and cleaved-caspase-3 expression, and upregulates Bcl-2 in H9C2 cardiomyocytes[4].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Sophocarpine Related Antibodies

    Cell Viability Assay[1]

    Cell Line: U251, C6 glioblastoma cells
    Concentration: 0.5, 1, 2, 4 mM
    Incubation Time: 24-48 h
    Result: Reduced cell viability in a dose- and time-dependent manner, with IC50 around 2 mM at 48 hours, as measured by CCK-8 assay.
    No significant cytotoxicity was observed in primary astrocytes at these concentrations.

    Apoptosis Analysis[1]

    Cell Line: U251 glioblastoma cells
    Concentration: 2 mM
    Incubation Time: 24 h
    Result: Resulted a significant increase in subG1 phase cells (apoptotic cells) and G0/G1 phase arrest.

    Western Blot Analysis[1][2]

    Cell Line: U251 glioblastoma cells[1] HCT116, SW620 colorectal cancer cells[2]
    Concentration: 2 mM for U251 cells; 0.4 mM for HCT116, SW620 cells
    Incubation Time: 24 h, 48 h
    Result: Upregulation of cleaved Caspase-3, P53, and downregulation of Bcl-2, indicating induction of intrinsic apoptosis in U251 cells[1].
    Downregulated phosphorylated MEK (p-MEK), phosphorylated ERK (p-ERK), N-cadherin, and MMP-9 in HCT116, SW620 cells, while VEGF-A/C/D secretion reduced[2].
    In Vivo

    Sophocarpine (35 mg/kg; intraperitoneal injection; once every 2 days; 2 weeks) inhibits tumor growth, upregulates PTEN expression, downregulates Akt phosphorylation, and induces tumor cell apoptosis in BALB/c nude mouse subcutaneous and orthotopic glioma transplantation models[1].
    Sophocarpine (10-30 mg/kg; intraperitoneal injection; twice a week; 4 weeks) improves cardiac function, reduced CK, CK-MB, and LDH levels, and alleviates oxidative stress and cardiomyocyte apoptosis in a DOX (HY-15142A)-induced cardiac injury model in C57BL/6J mice[4].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: BALB/c Nude Mouse Glioblastoma Xenograft Model (male, 18-24 g, 6-8 weeks old): subcutaneous and orthotopic U251 glioblastoma xenografts[1]
    Dosage: 35 mg/kg
    Administration: Intraperitoneal injection, every 2 days for 2 weeks (subcutaneous model); daily for 2 weeks (orthotopic model)
    Result: Significantly reduced subcutaneous tumor volume and weight by 50% compared to control.
    Echocardiography and histology showed no cardiotoxicity.
    Western blot in tumor tissues revealed upregulated PTEN and cleaved Caspase-3, downregulated p-Akt and Bcl-2, indicating activation of the PTEN/PI3K/Akt pathway to induce apoptosis.
    Immunohistochemistry confirmed reduced Ki-67 proliferation marker and increased PTEN expression.
    Animal Model: C57BL/6J Mouse Doxorubicin-Induced Heart Injury Model (male, 25 g, 7 weeks old): Doxorubicin (5 mg/kg weekly×4 weeks) induced cardiotoxicity[4]
    Dosage: 10 mg/kg or 30 mg/kg
    Administration: Intraperitoneal injection, co-administered with Doxorubicin weekly for the last 2 weeks (after initial 2 weeks of doxorubicin alone), total 4 weeks
    Result: Echocardiography showed improved left ventricular ejection fraction (LVEF) and fractional shortening (LVFS).
    Serum biomarkers CK, CK-MB, and LDH were reduced by 30-40% compared to doxorubicin group.
    DHE staining revealed decreased myocardial superoxide production, while MDA levels were lowered and SOD/GSH increased.
    Western blot showed upregulated Nrf2/HO-1 signaling, reduced NOX-4 and pro-apoptotic proteins (Bax, cleaved-caspase-3, Cyto-C), and increased anti-apoptotic Bcl-2 in heart tissues.
    Molecular Weight

    246.35

    Formula

    C15H22N2O
    CAS No.
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    O=C1C=CC[C@]2([H])[C@@]3([H])CCCN4[C@@]3([H])[C@](CCC4)([H])CN21
    Structure Classification
    Initial Source
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 2 years
    -20°C 1 year
    Solvent & Solubility
    In Vitro: 

    DMSO : 50 mg/mL (202.96 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    H2O : 10 mg/mL (40.59 mM; Need ultrasonic)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 4.0592 mL 20.2960 mL 40.5920 mL
    5 mM 0.8118 mL 4.0592 mL 8.1184 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.08 mg/mL (8.44 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.08 mg/mL (8.44 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

    For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  PBS

      Solubility: 10 mg/mL (40.59 mM); Clear solution; Need ultrasonic

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 99.75%

    SDS (419 KB)

    COA (254 KB) HNMR (252 KB) LCMS (94 KB)

    Handling Instructions (2659 KB)
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    H2O / DMSO 1 mM 4.0592 mL 20.2960 mL 40.5920 mL 101.4800 mL
    5 mM 0.8118 mL 4.0592 mL 8.1184 mL 20.2960 mL
    10 mM 0.4059 mL 2.0296 mL 4.0592 mL 10.1480 mL
    15 mM 0.2706 mL 1.3531 mL 2.7061 mL 6.7653 mL
    20 mM 0.2030 mL 1.0148 mL 2.0296 mL 5.0740 mL
    25 mM 0.1624 mL 0.8118 mL 1.6237 mL 4.0592 mL
    30 mM 0.1353 mL 0.6765 mL 1.3531 mL 3.3827 mL
    40 mM 0.1015 mL 0.5074 mL 1.0148 mL 2.5370 mL
    DMSO 50 mM 0.0812 mL 0.4059 mL 0.8118 mL 2.0296 mL
    60 mM 0.0677 mL 0.3383 mL 0.6765 mL 1.6913 mL
    80 mM 0.0507 mL 0.2537 mL 0.5074 mL 1.2685 mL
    100 mM 0.0406 mL 0.2030 mL 0.4059 mL 1.0148 mL

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Sophocarpine Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Sophocarpine6483-15-4AutophagyApoptosisNF-κBPI3KAktMEKERKPTENNuclear factor-κBNuclear factor-kappaBPhosphoinositide 3-kinasePKBProtein kinase BMitogen-activated protein kinase kinaseMAPKKMAP2KExtracellular signal regulated kinasesPhosphatase and tensin homologMMAC1Inhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Sophocarpine
    Cat. No.:
    HY-N0103
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (419 KB) Français - FR (419 KB) Deutsch - DE (419 KB) Norwegian - NO (419 KB) Español - ES (419 KB) Swedish - SV (419 KB) Italian - IT (419 KB) Portuguese - PT (419 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.